Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 1;8(2):e000847. doi: 10.1136/jitc-2020-000847

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Transient G1 arrest led to changes in the proportion of intratumor T-cell subsets favoring effector T-cell function. (A) Flow cytometric analysis of intratumor CD8⁺ T cells, CD4⁺ T cells, myeloid cell types (macrophages, mMDSC and gMDSC populations) and Tregs; (B) proportion of Treg in total tumor or spleen CD4⁺ T cells and (C) ratio of CD8⁺ T cells to Tregs (% CD8⁺ T cells/% Tregs) in the CD45⁺ population or spleen (n=5–8 tumors analyzed per treatment group and time point); and (D) proportion of activated (% CD69⁺) cells in CD8⁺ or CD4⁺ T cells. *P<0.05. gMDSC, granulocytic myeloid-derived suppressor cell; mMDSC, monocytic myeloid-derived suppressor cell; OP, oxaliplatin plus anti-programmed death-ligand-1; TOP, trilaciclib plus oxaliplatin and anti-programmed death-ligand-1; Treg, T-regulatory cell.